GoldenGolden
Bayer

Bayer

German multinational pharmaceutical, chemical, and agricultural biotechnology company

Bayer is a publicly-traded, multinational company headquartered in Leverkusen, Germany. Founded over 150 years ago, its core competencies presently lie in the life science fields of health care and agriculture.

Business Areas

The company's life science unit has 3 main divisions, pharmaceuticals, consumer health, and crop science. It also has an animal health unit as well as a corporate functions business services unit. Also, Bayer has a 60% stake in Currenta, a company offering services for the chemical industry, including utility supply, waste management, infrastructure, safety, security, analytics, and vocational training.

Pharmaceuticals

In terms of sales, Bayer's pharmaceuticals segment is the largest in the company. The focus of this segment is primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology, and ophthalmology. Principal research centers are located in Germany, the United States, Finland, and Norway.

Consumer Health

The consumer health division focuses on everyday healthcare, where the company has a portfolio of over 170 brands to treat minor illnesses. The products are in areas such as digestive health, allergies, skin conditions, pain management, nutritional supplements, and common colds.

Crop Science

Bayer's crop sciences division focuses on delivering solutions to farmers in areas such as crop protection, seeds, and traits, and digital farming. In June 2018, Bayer completed its acquisition of Monsanto for approximately $63 billion. In connection with regulatory approval processes, the company agreed to divest portions of its businesses to BASF.

Animal Health

The company's animal health unit develops and markets products and solutions for the prevention and treatment of diseases in companion and farm animals. In November 2018, Bayer announced its plan to sell the unit, which is estimated to be worth up to €7 billion, along with several other brands. The move is estimated to result in about 12,000 job cuts worldwide.

Business Services

Bayer's business services unit is an in-house center for business solutions and business support process. Its portfolio ranges from the development and implementation of IT-based solutions and design, building, and execution of end-to-end process operations to in-house management consulting.

Bayer LifeHubs

Bayer's LifeHubs are co-working, learning, and incubation spaces managed by Bayer. They are intended to be used by startups and prospective startup companies as a space to collaborate, learn more about industries and industry-specific challenges, and as a general co-working and meeting space. They have locations in Boston, California, Lyon, Berlin, Singapore, Japan, and Reading.

CoLaborator

The Bayer CoLaborator program is a startup incubation program. They offer startups co-working spaces located within their LifeHubs and elsewhere. They focus on engagement between life-science startups and Bayer researchers. They have CoLaborator locations in Berlin, Kobe, Moscow, and San Francisco for pharmaceutical startups. They have a location in West Sacramento for crop science startups.

myAgro

Bayer has supported myAgro, a non-profit investing in and providing services for the development of smallholder farmers. Their initial focus was in Mali. Part of myAgro's work has been enabling farmers to save small amounts for seed and fertilizer through a cellphone for those unable to have a bank account. They also work on nutrition and hygiene seminars and deworming programs.

Leadership

Timeline

June 8, 2021
Bayer’s Parkinson’s disease stem cell therapy officially lands in the clinic while another treatment for the neurodegenerative movement disorder is seeking patients
June 3, 2021
Bayer announces agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc.
May 18, 2021
Bayer announces that Brett Begemann, Chief Operating Officer, Crop Science, will retire from his role after 38 years with the company and Rodrigo Santos currently Head of Crop Science Commercial Operations, Latin America, will succeed Begemann.
December 1, 2020
Bayer and Blackford Analysis announce AI Platform agreement in Radiology.
November 18, 2020
Bayer and BlockApps launch blockchain initiative TraceHarvest Network - Business Insider.

.

June 24, 2020
Bayer says it will pay up to US$10.9 billion to settle litigation over the subsidiary Monsanto's weedkiller Roundup, which has faced thousands of lawsuits over claims it causes cancer.
October 1, 2019
Bayer says it is to spend more than 25 billion euros ($27.22 billion) on research and development at its agriculture unit over the next 10 years.

August 7, 2019
Reuters reported last September initial plans by Bayer to divest its 60% stake in the chemical park operator, part of a string of assets it has put on the block to slash debt since its $63 billion takeover of Monsanto last year.
June 2019
Bayer announces that it is planning to invest $5.6 billion over the next 10 years in research on weed control.
March 25, 2019
Johnson & Johnson and Bayer agree to pay $775 million to settle about 25,000 lawsuits involving the blood thinner Xarelto, which they jointly sell.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Amir Morani

Employee

Carmen Ionescu

Employee

Debra Lopez Quiat

Employee

Dr. Hartmut Klusik

Labor Director, Human Resources, Technology, & Sustainability

Heiko Schipper

President, Consumer Health Division

Kemal Malik

Innovation & Head of Latin America

Liam Condon

President, Crop Science Division & Animal Health Business Unit

Mary Kalnas

Employee

Stefan Oelrich

Head of Pharmaceuticals Division

Werner Baumann

Chairman & CEO

Wolfgang Nickl

CFO & Head of Asia Pacific and North America

Further reading

Title
Author
Link
Type
Date

Bayer Completes Monsanto Acquisition for $63 Billion

Web

Bayer to cut 12,000 jobs and sell brands

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

BlueRock Therapeutics

Emile F. Nuwaysir

Toronto

regenerative medicine

Casebia Therapeutics

Jim Burns

Cambridge, Massachusetts

gene-editing therapeutics

Joyn Bio

Michael Miille

Boston

probiotics for plants

News

Title
Author
Date
Publisher
Description
Mark Terry
June 9, 2021
BioSpace
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
Annalee Armstrong
June 8, 2021
FierceBiotech
Bayer's Parkinson's disease stem cell therapy has officially landed in the clinic while another treatment for the neurodegenerative movement disorder is seeking patients. The first dose of DA01was administered in a phase 1 clinical trial through Bayer subsidiary BlueRock Therapeutics. Bayer has also kicked off a gene therapy trial in Parkinson's disease through Asklepios BioPharmaceutical.
Alex Keown
June 8, 2021
BioSpace
Bayer is taking multiple shots at Parkinson's disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
Heather Landi
June 4, 2021
FierceHealthcare
Axtria pulled in $150 million to accelerate the development of AI-enabled software platforms, Caris Life Sciences hauled in a whopping $830 million, Noom bulked up with $540 million and other funding news in May.
Mark Terry
June 4, 2021
BioSpace
Bayer, like many biopharma companies, is presenting study results at the 2021 American Society of Clinical Oncology (ASCO) Annual meeting being held online June 4-8, 2021.
Brandon May
June 4, 2021
BioSpace
Bayer will nab exclusive rights to a differentiated alpha radionuclide, actinium-225 investigational compound, and a small molecule targeting prostate-specific membrane antigen.
Annalee Armstrong
June 3, 2021
FierceBiotech
Amid sliding sales for prostate cancer drug Xofigo, Bayer will bolster its portfolio of targeted alpha therapies with the acquisition of radiotherapeutics biotech Noria Therapeutics and subsidiary PSMA Therapeutics. The deal, of which financial details were not disclosed, will see Bayer pick up exclusive rights to two investigational therapies in prostate cancer that will complement the already approved therapy Xofigo, according to a release.
Natasha Lomas
May 27, 2021
TechCrunch
The digital health space continues cooking on gas: Berlin-based Ada Health has closed a $90M Series B round of funding led by Leaps by Bayer, the impact investment arm of the German multinational pharma giant, Bayer AG. Other investors in the round include Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures. The [...]
Callum Burroughs
May 27, 2021
Business Insider
Ada Health is raising fresh funding from the impact investing arm of German pharmaceutical giant Bayer.
Andrea Park
May 26, 2021
FierceBiotech
The Berlin-based company will use its latest cash infusion to expand in the U.S. and continue developing its artificial intelligence-powered symptom assessment technology. The goal? Getting closer to Ada's dream of becoming the world's top healthcare navigation platform.
BioSpace
May 26, 2021
BioSpace
Greentown Labs , the largest climatetech startup incubator in North America , today announced Bayer as the newest member of its growing corporate partner network.
May 18, 2021
BioSpace
Bayer Announces New Commercial Leaders for Crop Science Division to Accelerate Growth and Drive Business Transformation - read this article along with other careers information, tips and advice on BioSpace
May 17, 2021
TCTMD.com
More than quoting statistics and pointing to gaps, the all-female commission set out 10 recommendations for meaningful change.
May 17, 2021
WebWire
Applications are now open for the 2021 Youth Ag Summit, a global forum and biennially organized conference where young leaders collaborate to develop sustainable solutions for food security and global agriculture as they work toward becoming global instruments of change., , , , While this is the 5th biennial Youth Ag Summit, it will be the first virtual YAS event. This year's cohort will also benefit from another exciting YAS first. As an official global partner with Bayer for this year's for...
Dan Taylor
May 12, 2021
Tech.eu
London-based Huma Therapeutics has closed a Series C funding round at $130 million. Led by Leaps by Bayer and Hitachi Ventures, Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, and HAT Technology & Innovation Fund by HAT, also participated, as well as individual investors Nikesh Arora and Michael Diekmann. As part of the round, [...]
Recursion Pharmaceuticals
May 12, 2021
www.prnewswire.com:443
/PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological...
Ingrid Lunden
May 11, 2021
TechCrunch
While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology. Huma, which combines data [...]
Ingrid Lunden
May 11, 2021
TechCrunch
While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology. Huma, which combines data [...]
Huma
May 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The...
Christine Hall
May 11, 2021
Crunchbase News
Huma's digital hospital at home was co-created with clinicians and independently shown to almost double clinical capacity and reduce readmissions.
SHOW MORE

References

Page 1 of 3
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.